Open Payments

The Moses H. Cone Memorial Hospital

Type
Teaching hospital
Where
Greensboro, NC
Medicare CCN
340091
Received
$1,301,834 in 441 records, 2021 ($81,140 general, $1,220,693 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2021General payment54$81,140
2021Research payment387$1,220,693

By company

CompanyRecordsAmountYears
Novartis Pharmaceuticals Corporation4$347,4702021
CVRx, Inc.9$200,0012021
CSL Behring31$168,4492021
Amgen Inc.6$92,7362021
Esperion Therapeutics, Inc.208$71,0372021
LivaNova USA, Inc.14$66,6802021
Medtronic, Inc.10$59,4092021
Gilead Sciences, Inc.15$47,2762021
Johnson & Johnson Health Care Systems Inc.17$36,9272021
Varian Medical Systems, Inc.1$30,0002021
Boehringer Ingelheim International GmbH4$20,3722021
E.R. Squibb & Sons, L.L.C.1$20,2922021
Daiichi Sankyo Inc.19$18,2542021
PFIZER INC.28$16,8002021
Boehringer Ingelheim Pharma GmbH & Co.KG3$16,2652021
SANOFI PASTEUR INC.1$15,2952021
Edwards Lifesciences Corporation3$13,1212021
Siemens Medical Solutions USA, Inc.8$10,1572021
BIOTRONIK INC.24$10,0072021
AstraZeneca UK Limited2$8,9312021
Tandem Diabetes Care, Inc.18$8,5002021
Genentech, Inc.3$8,4022021
Aesculap Implant Systems, LLC1$7,3002021
Boehringer Ingelheim Pharmaceuticals, Inc.1$2,5002021
Surmodics, Inc.3$2,1442021
Roche Diagnostics Corporation1$1,0002021
Myriad Genetic Laboratories, Inc.1$1,0002021
Hill-Rom Company, Inc1$5892021
Abbott Laboratories1$4142021
Smith+Nephew, Inc.1$4002021
AstraZeneca Pharmaceuticals LP1$522021
Zimmer Biomet Holdings, Inc.1$452021

By nature of payment

NatureRecordsAmount
Research payment387$1,220,693
Debt forgiveness20$45,231
Compensation for services other than consulting, including serving as faculty or as a speaker at a v25$17,790
Long term medical supply or device loan2$10,621
Space rental or facility fees (teaching hospital only)5$7,400
Charitable Contribution1$52
Gift1$45

Records

DateCompanyAmountNatureFormProductStudyYear
2021-12-31Medtronic, Inc.$19,505Research paymentIn-kind items and servicesReveal LINQ Device, Cardiac Diagnostics and MonitoringALLEVIATE-HF2021
2021-12-31Edwards Lifesciences Corporation$5,325Long term medical supply or device loanIn-kind items and servicesHemoSphere Device, Hemodynamic Monitoring2021
2021-12-31Edwards Lifesciences Corporation$5,296Long term medical supply or device loanIn-kind items and servicesHemoSphere Device, Hemodynamic Monitoring2021
2021-12-31Siemens Medical Solutions USA, Inc.$867Research paymentCash or cash equivalentEclipse Treatment Planning System for External Beam Radiation Therapy Device, Oncology2021
2021-12-31AstraZeneca UK Limited$9Research paymentIn-kind items and servicesA Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib Fulvestrant Versus Placebo 2021
2021-12-29Tandem Diabetes Care, Inc.$250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2021
2021-12-22Novartis Pharmaceuticals Corporation$17,907Research paymentCash or cash equivalentLEQVIO Drug, CARDIOVASCULARAN OPEN-LABEL EXTENSION TRIAL OF THE PHASE III LIPID-LOWERING TRIALS TO ASSESS THE EFFECT OF LONG TERM DOSING OF INCLISI2021
2021-12-22Gilead Sciences, Inc.$1,173Research paymentCash or cash equivalentA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2021
2021-12-22Johnson & Johnson Health Care Systems Inc.$205Debt forgivenessIn-kind items and services2021
2021-12-15Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-12-15Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-12-15Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-12-15Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-12-15Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-12-15Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-12-15Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-12-15Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-12-15Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-12-15Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-12-15Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-12-15Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-12-15Esperion Therapeutics, Inc.$75Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-12-15Esperion Therapeutics, Inc.$75Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-12-15Esperion Therapeutics, Inc.$75Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-12-10PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2021
2021-12-09Medtronic, Inc.$130Research paymentCash or cash equivalentReveal LINQ Device, Cardiac Diagnostics and MonitoringALLEVIATE-HF2021
2021-12-08CSL Behring$8,097Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2021
2021-12-08Daiichi Sankyo Inc.$5,833Research paymentCash or cash equivalentSAVAYSA Drug, ThrombosisENVISAGE2021
2021-12-08Daiichi Sankyo Inc.$2,500Research paymentCash or cash equivalentSAVAYSA Drug, ThrombosisENVISAGE2021
2021-12-08Daiichi Sankyo Inc.$1,000Research paymentCash or cash equivalentSAVAYSA Drug, ThrombosisENVISAGE2021
2021-12-08Daiichi Sankyo Inc.$925Research paymentCash or cash equivalentSAVAYSA Drug, ThrombosisENVISAGE2021
2021-12-08Daiichi Sankyo Inc.$875Research paymentCash or cash equivalentSAVAYSA Drug, ThrombosisENVISAGE2021
2021-12-08Daiichi Sankyo Inc.$530Research paymentCash or cash equivalentSAVAYSA Drug, ThrombosisENVISAGE2021
2021-12-08Daiichi Sankyo Inc.$500Research paymentCash or cash equivalentSAVAYSA Drug, ThrombosisENVISAGE2021
2021-12-08CSL Behring$150Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2021
2021-12-03LivaNova USA, Inc.$2,930Research paymentCash or cash equivalentVNS - Vitaria Device, Cardiology/Vascular DiseasesANTHEM HFrEF2021
2021-12-01Tandem Diabetes Care, Inc.$600Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2021
2021-12-01Boehringer Ingelheim International GmbH$160Research paymentIn-kind items and servicesEmpagliflozin for prevention of HHF and death after an AMI2021
2021-11-30Boehringer Ingelheim Pharma GmbH & Co.KG$3,253Research paymentIn-kind items and servicesJARDIANCE Drug, DIABETESEmpagliflozin for prevention of HHF and death after an AMI2021
2021-11-30PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2021
2021-11-29CSL Behring$23,977Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2021
2021-11-29CSL Behring$850Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2021
2021-11-24Boehringer Ingelheim International GmbH$9,928Research paymentCash or cash equivalentJARDIANCE Drug, DIABETESEmpagliflozin for prevention of HHF and death after an AMI2021
2021-11-22Hill-Rom Company, Inc$589Debt forgivenessCash or cash equivalentThe Vest System 205 Acute Care Device, Airway Clearance Device2021
2021-11-22Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-11-22Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-11-22Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-11-22Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-11-22Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-11-22Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-11-22Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-11-22Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-11-22Esperion Therapeutics, Inc.$343Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-11-22Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-11-22Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-11-22Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-11-22Esperion Therapeutics, Inc.$75Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-11-18CSL Behring$90Research paymentIn-kind items and servicesA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2021
2021-11-17Gilead Sciences, Inc.$1,173Research paymentCash or cash equivalentA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2021
2021-11-11Surmodics, Inc.$377Research paymentCash or cash equivalentSurVeil Device, drug-coated balloonTRANSCEND2021
2021-11-05LivaNova USA, Inc.$4,580Research paymentCash or cash equivalentVNS - Vitaria Device, Cardiology/Vascular DiseasesANTHEM HFrEF2021
2021-11-02CVRx, Inc.$35,000Research paymentIn-kind items and servicesBarostim Neo System Device, Heart Failure and Hypertension2021
2021-11-01Boehringer Ingelheim International GmbH$2,284Research paymentCash or cash equivalentJARDIANCE Drug, DIABETESEmpagliflozin for prevention of HHF and death after an AMI2021
2021-10-31Boehringer Ingelheim Pharma GmbH & Co.KG$3,253Research paymentIn-kind items and servicesJARDIANCE Drug, DIABETESEmpagliflozin for prevention of HHF and death after an AMI2021
2021-10-26CSL Behring$750Research paymentIn-kind items and servicesA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2021
2021-10-26PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2021
2021-10-26PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2021
2021-10-26PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2021
2021-10-21Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-10-21Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-10-21Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-10-21Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-10-21Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-10-21Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-10-21Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-10-21Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-10-21Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-10-21Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-10-21Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-10-21Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-10-21Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-10-21Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-10-21Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-10-21Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-10-21Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-10-21Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-10-21Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-10-21Esperion Therapeutics, Inc.$343Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-10-21Esperion Therapeutics, Inc.$343Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-10-21Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-10-21Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-10-21Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-10-21Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-10-21Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-10-21Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-10-21Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-10-21Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-10-21Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-10-21Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-10-21Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-10-21Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-10-21Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-10-21Esperion Therapeutics, Inc.$75Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-10-21Esperion Therapeutics, Inc.$75Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-10-19CVRx, Inc.$28,000Research paymentIn-kind items and servicesBarostim Neo System Device, Heart Failure and Hypertension2021
2021-10-18CVRx, Inc.$9,841Research paymentCash or cash equivalentBarostim Neo System Device, Heart Failure and Hypertension2021
2021-10-18Johnson & Johnson Health Care Systems Inc.$3,889Debt forgivenessIn-kind items and services2021
2021-10-13CSL Behring$22,712Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2021
2021-10-13CSL Behring$950Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2021
2021-10-11Medtronic, Inc.$3,840Research paymentCash or cash equivalentReveal LINQ Device, Cardiac Diagnostics and MonitoringStroke AF2021
2021-10-06Tandem Diabetes Care, Inc.$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2021
2021-09-30SANOFI PASTEUR INC.$15,295Research paymentCash or cash equivalentSTA00011 Stamaril Yellow Fever2021
2021-09-30Medtronic, Inc.$749Research paymentCash or cash equivalentReveal LINQ Device, Cardiac Diagnostics and MonitoringALLEVIATE-HF2021
2021-09-29Tandem Diabetes Care, Inc.$1,150Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2021
2021-09-21Johnson & Johnson Health Care Systems Inc.$330Debt forgivenessIn-kind items and services2021
2021-09-17PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2021
2021-09-17PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2021
2021-09-17PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2021
2021-09-17PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2021
2021-09-17PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2021
2021-09-16CVRx, Inc.$28,000Research paymentIn-kind items and servicesBarostim Neo System Device, Heart Failure and Hypertension2021
2021-09-15CSL Behring$25,253Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2021
2021-09-15CSL Behring$1,050Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2021
2021-09-08LivaNova USA, Inc.$1,346Research paymentCash or cash equivalentVNS - Vitaria Device, Cardiology/Vascular DiseasesANTHEM HFrEF2021
2021-09-01Surmodics, Inc.$1,390Research paymentCash or cash equivalentSurVeil Device, drug-coated balloonTRANSCEND2021
2021-08-31Boehringer Ingelheim Pharma GmbH & Co.KG$9,759Research paymentIn-kind items and servicesJARDIANCE Drug, DIABETESEmpagliflozin for prevention of HHF and death after an AMI2021
2021-08-27Genentech, Inc.$949Research paymentCash or cash equivalentHerceptin Biological, BioOncologyA PHASE III TRIAL IN ADJUVANT HER2 BC PTS2021
2021-08-26CSL Behring$565Research paymentIn-kind items and servicesA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2021
2021-08-24Johnson & Johnson Health Care Systems Inc.$2,245Debt forgivenessIn-kind items and services2021
2021-08-24PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2021
2021-08-23Johnson & Johnson Health Care Systems Inc.$122Debt forgivenessIn-kind items and services2021
2021-08-19Surmodics, Inc.$377Research paymentCash or cash equivalentSurVeil Device, drug-coated balloonTRANSCEND2021
2021-08-18Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-08-18Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-08-18Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-08-18Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-08-18Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-08-18Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-08-18Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-08-18Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-08-18Esperion Therapeutics, Inc.$75Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-08-16Boehringer Ingelheim Pharmaceuticals, Inc.$2,500Space rental or facility fees (teaching hospital only)Cash or cash equivalent2021
2021-08-13CSL Behring$14,223Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2021
2021-08-13Genentech, Inc.$6,000Research paymentCash or cash equivalentHerceptin Biological, BioOncologyA PHASE III TRIAL IN ADJUVANT HER2 BC PTS2021
2021-08-13CSL Behring$450Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2021
2021-08-13Esperion Therapeutics, Inc.$67Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-08-12AstraZeneca UK Limited$8,922Research paymentCash or cash equivalentA Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib Fulvestrant Versus Placebo 2021
2021-08-05Siemens Medical Solutions USA, Inc.$1,260Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2021
2021-08-05Siemens Medical Solutions USA, Inc.$200Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentARIA Radiation Therapy Management Software Device, Oncology2021
2021-08-04LivaNova USA, Inc.$6,144Research paymentCash or cash equivalentVNS - Vitaria Device, Cardiology/Vascular DiseasesANTHEM HFrEF2021
2021-08-03Aesculap Implant Systems, LLC$7,300Debt forgivenessCash or cash equivalent2021
2021-07-28CVRx, Inc.$7,878Research paymentCash or cash equivalentBarostim Neo System Device, Heart Failure and Hypertension2021
2021-07-28Tandem Diabetes Care, Inc.$1,050Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2021
2021-07-27CSL Behring$431Research paymentIn-kind items and servicesA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2021
2021-07-26PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2021
2021-07-26PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2021
2021-07-26PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2021
2021-07-22Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-07-22Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-07-22Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-07-22Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-07-22Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-07-22Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-07-22Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-07-22Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-07-22Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-07-22Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-07-22Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-07-22Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-07-22Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-07-22Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-07-22Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-07-22Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-07-22Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-07-22Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-07-22Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-07-22Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-07-22Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-07-22Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-07-22Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-07-20Esperion Therapeutics, Inc.$39Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-07-16CSL Behring$2,205Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2021
2021-07-16CSL Behring$50Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2021
2021-07-13Medtronic, Inc.$49Research paymentCash or cash equivalentReveal LINQ Device, Cardiac Diagnostics and MonitoringStroke AF2021
2021-07-12Medtronic, Inc.$5,602Research paymentCash or cash equivalentReveal LINQ Device, Cardiac Diagnostics and MonitoringALLEVIATE-HF2021
2021-07-09Siemens Medical Solutions USA, Inc.$1,500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSOMATOM go.Top Device, CT and RO incl. Computed Tomography and Radiation Oncology2021
2021-07-07Tandem Diabetes Care, Inc.$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2021
2021-07-02CVRx, Inc.$35,000Research paymentIn-kind items and servicesBarostim Neo System Device, Heart Failure and Hypertension2021
2021-06-30Medtronic, Inc.$6,495Research paymentIn-kind items and servicesReveal LINQ Device, Cardiac Diagnostics and MonitoringALLEVIATE-HF2021
2021-06-30LivaNova USA, Inc.$2,692Research paymentCash or cash equivalentVNS - Vitaria Device, Cardiology/Vascular DiseasesANTHEM HFrEF2021
2021-06-30Tandem Diabetes Care, Inc.$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2021
2021-06-28Smith+Nephew, Inc.$400Space rental or facility fees (teaching hospital only)Cash or cash equivalent2021
2021-06-25Amgen Inc.$7,060Research paymentCash or cash equivalentGALACTIC - HF2021
2021-06-24Zimmer Biomet Holdings, Inc.$45GiftIn-kind items and servicesZimmer Biomet Instruments and Implants Device, General2021
2021-06-23Gilead Sciences, Inc.$1,282Research paymentCash or cash equivalentBiktarvy Drug, HIVA Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena2021
2021-06-23Gilead Sciences, Inc.$630Research paymentCash or cash equivalentBiktarvy Drug, HIVA Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricita2021
2021-06-22Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-06-22Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-06-22Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-06-22Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021

The latest 200 records of 441.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Guilford CountyGreensboro city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Greensboro, NC, county Guilford County, NC, state North Carolina; placed by its city name.

MeasurePlace (city or town)
Greensboro, NC
County
Guilford County, NC
State
North Carolina
Population B01003301,198547,94010,730,404
Population, 2020 census P1299,035541,29910,439,388
Median age B0100234.337.539.1
Under 18 B0100121.7%22.0%21.8%
65 and over B0100114.4%15.9%17.2%
Households B11001123,984219,7184,282,345
Foreign born B0500212.7%11.8%9.1%
Median household income B19013$61,515$68,642$72,388
Median family income B19113$80,585$88,156$90,290
Per capita income B19301$37,531$39,376$41,385
Poverty rate B1700117.0%14.6%13.0%
Unemployment rate B230255.1%4.6%4.7%
Civilian labor force B23025158,568282,3625,336,863
Mean commute (minutes) B0801321.722.025.1
Bachelor's degree or higher B1500341.0%39.0%35.7%
Housing units B25001135,665238,0324,895,668
Owner-occupied B2500350.5%59.9%66.6%
Renters B2500349.5%40.1%33.4%
Median home value B25077$244,800$259,900$288,900
Median gross rent B25064$1,172$1,163$1,228
White, not Hispanic B0300238.1%46.0%60.0%
Black B0300241.0%33.5%20.0%
Hispanic or Latino B0300210.5%10.1%11.3%
Asian B030025.2%5.4%3.3%
American Indian and Alaska Native B030020.2%0.1%0.8%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Greensboro, NC.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.